Volume | 1,500,200 |
|
|||||
News | (1) | ||||||
Day High | 125.13 | Low High |
|||||
Day Low | 117.21 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sarepta Therapeutics Inc New | SRPT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
117.66 | 117.21 | 125.13 | 124.25 | 117.12 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
21,799 | 1,500,200 | $ 120.71 | $ 181,091,722 | - | 55.25 - 159.89 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:58:55 | 80 | $ 124.24 | USD |
Sarepta Therapeutics (SRPT) Options Flow Summary
Sarepta Therapeutics Inc New Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
11.66B | 93.86M | - | 1.24B | -535.98M | -5.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sarepta Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRPT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 117.00 | 125.13 | 114.37 | 116.81 | 628,786 | 7.25 | 6.20% |
1 Month | 129.25 | 131.16 | 114.37 | 123.11 | 625,658 | -5.00 | -3.87% |
3 Months | 120.76 | 143.00 | 114.37 | 126.28 | 808,349 | 3.49 | 2.89% |
6 Months | 111.63 | 143.00 | 55.25 | 99.97 | 1,327,485 | 12.62 | 11.31% |
1 Year | 127.17 | 159.89 | 55.25 | 110.26 | 1,254,836 | -2.92 | -2.30% |
3 Years | 71.37 | 159.89 | 55.25 | 102.02 | 1,107,173 | 52.88 | 74.09% |
5 Years | 118.20 | 181.83 | 55.25 | 106.71 | 1,145,274 | 6.05 | 5.12% |
Sarepta Therapeutics Description
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. |